JP2016528217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528217A5 JP2016528217A5 JP2016529868A JP2016529868A JP2016528217A5 JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5 JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- nucleoside analog
- combination
- taxane
- activated prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 claims 10
- 230000001146 hypoxic Effects 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229940002612 prodrugs Drugs 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 239000002777 nucleoside Substances 0.000 claims 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 229960001592 Paclitaxel Drugs 0.000 claims 4
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 230000003442 weekly Effects 0.000 claims 1
Claims (13)
- 低酸素活性化プロドラッグおよびタキサンを含んでなる、膵臓癌の治療における同時使用または連続使用のための組合せ医薬。
- ヌクレオシドアナログ化学療法剤をさらに含む、請求項１記載の組合せ医薬。
- 低酸素活性化プロドラッグがTH-302である、請求項１または２記載の組合せ医薬。
- タキサンがパクリタキセルまたはnab-パクリタキセルである、請求項１〜３いずれか記載の組合せ医薬。
- ヌクレオシドアナログ化学療法剤がゲムシタビンである、請求項２〜４いずれか記載の組合せ医薬。
- 低酸素活性化プロドラッグが、タキサンの少なくとも約30分前に投与される、請求項１〜５いずれか記載の組合せ医薬。
- 低酸素活性化プロドラッグが、ヌクレオシドアナログ化学療法剤の少なくとも約30分前に投与される、請求項２〜５いずれか記載の組合せ医薬。
- 低酸素活性化プロドラッグ、タキサン、および任意にヌクレオシドアナログ化学療法剤が、複数のサイクルで投与され、該複数のサイクルのそれぞれが、低酸素活性化プロドラッグ、タキサンおよび任意にヌクレオシドアナログ化学療法剤のそれぞれを、1週間に少なくとも1回で連続3週間にわたり連続的に投与し、次いで低酸素活性化プロドラッグ、タキサンおよび任意にヌクレオシドアナログ化学療法剤のいずれも1週間投与しないことを含む、請求項６または７記載の組合せ医薬。
- 低酸素活性化プロドラッグがTH-302であり、タキサンがnab-パクリタキセルであり、ヌクレオシドアナログ化学療法剤がゲムシタビンである、請求項２〜８いずれか記載の組合せ医薬。
- 癌が膵管腺癌である、請求項１〜９いずれか記載の組合せ医薬。
- 癌の治療のための組合せ医薬の製造における、低酸素活性化プロドラッグ、タキサン、および任意にヌクレオシドアナログ化学療法剤の使用。
- 低酸素活性化プロドラッグがTH-302であり、タキサンがnab-パクリタキセルであり、ヌクレオシドアナログ化学療法剤がゲムシタビンである、請求項１１記載の使用。
- 癌が膵管腺癌である、請求項１１または１２記載の使用。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361859152P | 2013-07-26 | 2013-07-26 | |
| US61/859,152 | 2013-07-26 | ||
| US201361887873P | 2013-10-07 | 2013-10-07 | |
| US61/887,873 | 2013-10-07 | ||
| US201461994295P | 2014-05-16 | 2014-05-16 | |
| US61/994,295 | 2014-05-16 | ||
| PCT/US2014/047885 WO2015013448A1 (en) | 2013-07-26 | 2014-07-23 | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528217A JP2016528217A (ja) | 2016-09-15 |
| JP2016528217A5 true JP2016528217A5 (ja) | 2017-08-31 |
Family
ID=51299053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529868A Pending JP2016528217A (ja) | 2013-07-26 | 2014-07-23 | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160158253A1 (ja) |
| EP (1) | EP3024490A1 (ja) |
| JP (1) | JP2016528217A (ja) |
| CN (1) | CN105792845A (ja) |
| WO (1) | WO2015013448A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017192863A1 (en) * | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| CN106279321A (zh) | 2016-08-09 | 2017-01-04 | 南京医科大学 | 吉西他滨ProTide乏氧活化前药及其应用 |
| CN110168658B (zh) * | 2016-10-05 | 2024-04-02 | 皇家飞利浦有限公司 | 患者监测系统和方法 |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| WO2023025312A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| CN117651548A (zh) | 2021-08-27 | 2024-03-05 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| CA2130578A1 (en) | 1992-04-17 | 1993-10-28 | Geewananda P. Gunawardana | Taxol derivatives |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| NZ521851A (en) | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| EP1680394A4 (en) | 2003-10-31 | 2006-10-11 | Auckland Uniservices Ltd | NOVEL NITROPHENYL MUSTARD AND NOVEL NITROPHENYLAZIRIDINE ALCOHOLS, CORRESPONDING PHOSPHATES AND USE THEREOF AS TARGET CYTOTOXIC AGENTS |
| PT1896040E (pt) | 2005-06-29 | 2012-09-27 | Threshold Pharmaceuticals Inc | Pró-fármacos de alquilador de fosforamidato |
| JP2009510165A (ja) | 2005-10-03 | 2009-03-12 | ジェネティックス ファーマシューティカルズ， インク． | 低酸素細胞を選択的に枯渇させるための方法 |
| ES2884044T3 (es) | 2006-12-26 | 2021-12-10 | Immunogenesis Inc | Profármaco alquilante de fosforamidato para el tratamiento del cáncer |
| ES2884674T3 (es) * | 2008-10-21 | 2021-12-10 | Immunogenesis Inc | Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed |
| SG186112A1 (en) * | 2010-06-04 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| MX2012014416A (es) | 2010-06-28 | 2013-02-27 | Threshold Pharmaceuticals Inc | Tratamiento de cancer de sangre. |
| US20140010805A1 (en) | 2010-07-12 | 2014-01-09 | Karen Curd | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| CN103458896B (zh) | 2011-04-01 | 2016-02-10 | 施瑞修德制药公司 | 用于治疗癌症的方法 |
| BR112013025969A2 (pt) | 2011-04-15 | 2016-12-20 | Threshold Pharmaceuticals Inc | forma de dose unitária para administração oral |
| WO2013096687A1 (en) | 2011-12-22 | 2013-06-27 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer |
| WO2013096684A1 (en) | 2011-12-22 | 2013-06-27 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs and mtor inhibitors for treating cancer |
| US20160045522A1 (en) | 2012-02-21 | 2016-02-18 | Threshold Pharmaceuticals, Inc. | Treatment of Cancer |
-
2014
- 2014-07-23 WO PCT/US2014/047885 patent/WO2015013448A1/en active Application Filing
- 2014-07-23 US US14/907,190 patent/US20160158253A1/en not_active Abandoned
- 2014-07-23 JP JP2016529868A patent/JP2016528217A/ja active Pending
- 2014-07-23 CN CN201480053041.5A patent/CN105792845A/zh active Pending
- 2014-07-23 EP EP14748448.9A patent/EP3024490A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528217A5 (ja) | ||
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| NZ738149A (en) | Use of exosomes for the treatment of disease | |
| BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| JP2014141525A5 (ja) | ||
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| ZA201508454B (en) | Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| ZA201703562B (en) | Pharmaceutical composition for oral administration comprising taxane | |
| JP2017527582A5 (ja) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2018522028A5 (ja) | ||
| HRP20201691T1 (hr) | Antitumorni agens koji uključuje irinotekan hidroklorid hidrat | |
| EP3348643A4 (en) | MODIFIED INTERLEUKIN 12 AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| HK1255345A1 (zh) | 含有高濃度紫杉烷的用於口服給藥的藥物組合物 | |
| BR112016016932A2 (pt) | Tratamento de neoplasia | |
| MA43178A (fr) | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci | |
| IL267775A (en) | Combined treatment with a Lantrin-1 interfering drug and immune checkpoint inhibitor drugs | |
| JP2019518052A5 (ja) |